Loading patent…
AssigneeSloan-Kettering Institute for Cancer Research
InventorsEthan Dmitrovsky, Raymond P. Warrell, Jr., Wilson H. Miller, Jr., Stanley Frankel
Estimating the term…
The present invention provides a method of diagnosing APL in a subject which comprises detecting in a sample from the subject either nucleic acid encoding an abnormal RAR-.alpha. receptor or an expressed protein encoded thereby. The present invention also provides methods of identifying a subject with APL who will or will not respond to treatment with a retinoid, as well as a subjects with APL who do not express a detectable t(15;17) translocation but will or will not respond to treatment with a retinoid. In addition, the present invention provides methods for monitoring the activity of APL and the process of treatment of APL. The present invention provides methods of identifying a subject with a neoplastic condition other than APL who will or will not respond to treatment with a retinoid as well as methods for monitoring the level of disease activity and progress and adequacy of treatment of a neoplastic condition. Lastly, the present invention provides a method for inhibiting the growth of a neoplastic cell.
A method of identifying a subject with acute promyelocytic leukemia resulting from a t(15;17) translocation who will respond to treatment with all-trans retinoic acid comprising steps of:
A method of identifying a subject with indications of acute promyelocytic leukemia who will not respond to treatment with all-trans retinoic acid comprising steps of:
Dependencies are inferred from the claim text.